PLA-Inhibitors (stoPLA): New class of NSAIDs for oral and transdermal pain treatment
Phospholipase A2 (PLA2) designates a large and diverse
group of enzymes that cleave phospholipids at the sn-2- position. This metabolic step is instrumental in a variety of pathogenic processes causing pain, fever and inflammation. Presently glucocortidoids are used for inhibition of PLA2. Unfortunately, glucocortidoids have serious side effects which limit their use as medication for pain treatment. stoPLA is a new class of heteroaryl-substituted acetone derivatives for the effective inhibition of PLA2, especially of cytosolic PLA2. These compounds effectively interact with the synthesis of prostaglandins and leukotrienes and reduce inflammatory processes. The new heteroarylsubstituted acetone derivatives have also an excellent solubility profile and are stable against metabolic inactivation through ketogroup reduction.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Targeted use of enfortumab vedotin for the treatment of advanced urothelial carcinoma
New study identifies NECTIN4 amplification as a promising biomarker – Under the leadership of PD Dr. Niklas Klümper, Assistant Physician at the Department of Urology at the University Hospital Bonn…
A novel universal light-based technique
…to control valley polarization in bulk materials. An international team of researchers reports in Nature a new method that achieves valley polarization in centrosymmetric bulk materials in a non-material-specific way…
How evolution has optimised the magnetic sensor in birds
The magnetic sense of migratory birds is probably based on the protein cryptochrome 4, and a genetic study has now provided further support for this theory. A team of researchers…
